About CRESP INJECTION DARBEPOETIN
Cresp is manufactured By Dr. Reddys. Cresp contains Darbepoetin alfa injection.
Cresp is the worlds first generic version of darbepoetin alpha in the world and the only darbepoetin alfa in India. Darbepoetin alfa is a modified version of epoetin alfa, which is engineered to have a longer half life, increasing (up to 3 times) the time it remains in the blood. This results in a reduced frequency of doses, providing a simpler and more convenient treatment option for patients and physicians as compared to treatment of anaemia with epoetin which is the current standard of care in India..............
Other Information
- Minimum Order Quantity: 1
- Port of Dispatch: New Delhi, India
Product Features and StrengthsCRESP INJECTION DARBEPOETIN is available in multiple strengths, allowing flexibility in dosage based on individual patient needs. Its biotechnological origin ensures consistent quality and efficacy. The formula is clear, colorless, odorless, and maintains a neutral pH, making it reliable and easy to administer. The product is distributed widely in India by reputable suppliers and exporters.
Indication and Mechanism of ActionIntended for anemia associated with chronic kidney disease, CRESP works by stimulating erythropoiesis through its action as an erythropoietin receptor agonist. This process encourages the production of red blood cells, helping patients manage and recover from anemia more effectively.
Safety, Storage, and Shelf LifeThe product must be stored refrigerated at 2C to 8C and should not be frozen. With a shelf life of 24 months, it remains a long-lasting option for healthcare settings. Usage precautions include regular hemoglobin monitoring and avoidance in patients with uncontrolled hypertension or pure red cell aplasia. Always use under medical supervision as prescribed.
FAQs of CRESP INJECTION DARBEPOETIN:
Q: How should CRESP INJECTION DARBEPOETIN be administered?
A: CRESP INJECTION DARBEPOETIN should be administered either subcutaneously or intravenously as directed by a healthcare provider. The precise route and dosage depend on individual patient requirements and medical supervision.
Q: What is the primary indication for using CRESP INJECTION DARBEPOETIN?
A: This injection is prescribed for treating anemia associated with chronic kidney disease, helping to stimulate red blood cell production and improve hemoglobin levels.
Q: When is CRESP INJECTION contraindicated for patients?
A: CRESP INJECTION DARBEPOETIN should not be used in patients with uncontrolled hypertension, hypersensitivity to darbepoetin alfa, or those diagnosed with pure red cell aplasia.
Q: Where should CRESP INJECTION be stored to maintain its effectiveness?
A: The injection must be stored refrigerated between 2C and 8C. It is important not to freeze the product to preserve its stability and potency.
Q: What are the benefits of using CRESP INJECTION DARBEPOETIN in anemia treatment?
A: The key benefit of CRESP INJECTION is its ability to stimulate erythropoiesis, supporting the increase of red blood cell counts and improving anemia symptoms among patients with chronic kidney disease.
Q: How often should hemoglobin be monitored when using CRESP INJECTION DARBEPOETIN?
A: Hemoglobin levels should be monitored regularly during therapy to ensure safe and effective treatment, and to mitigate potential risks associated with overcorrection.